The iLet Bionic Pancreas System is a dual-chamber infusion pump that autonomously calculates and commands doses of insulin and glucagon for precise and accurate subcutaneous delivery. It has been granted breakthrough designation for all configurations, including use with Zealand Pharma's dasiglucagon. Beta Bionics is a public benefit corporation committed to providing safe and effective autonomous glycemic control solutions to the type 1 diabetes community. Its public benefit mission includes bringing its technology to as many people with T1D as possible in an expeditious and responsible manner, continuing to innovate and offer the latest advances, and acting in the best possible interest of the T1D community. The company believes that pursuing its public benefit mission will result in a healthier and happier T1D community, and its investors support its structure.